Management of older (? 50 years old) HIV-infected individuals is becoming increasingly complex as many develop multiple HIV-associated-non-AIDS-defining (HANA) comorbidities at an earlier onset. We will utilize frailty measurements and neuropsychological performance (NP) tests to determine if a combination of cognitive impairment and frailty identifies vulnerable older HIV-infected individuals (n=130). In addition, we will employ innovative brain imaging techniques [including arterial spin labeling magnetic resonance imaging (ASL-MRI) and positron emission tomography using Pittsburgh B compound (PET-PiB)] to quantitatively assess perfusion and amyloid deposition in older HIV-infected individuals. We will evaluate if frailty correlates with neuroimaging biomarkers (ASL and PET-PIB) of brain integrity in older HIV-infected patients. Finally, we will determine at three year follow-up if frail older HIV-infected individuals have greater rates of change from baseline in cognitive impairment (NP testing), amyloid deposition (PET-PiB), and perfusion (ASL-MRI) compared to pre-frail or non-frail older HIV-infected individuals. This proposal will place HIV associated changes in frailty and cognition into the mainstream of national brain aging research. We will develop biomarkers that will allow for early detection of changes in brain function at the pre-frail state. It is hoped that these biomarkers will assist in the early administration of tailoed effective interventions.
Contemporary care of older (? 50 years old) HIV-infected patients has become complex and is characterized by the early onset of HIV associated non-AIDS (HANA) conditions. This proposal will: 1) increase our knowledge concerning the interaction between frailty and neuropsychological performance in older HIV-infected individuals;2) assess the relationship between frailty and neuroimaging markers of amyloid deposition and cerebral blood. These results could assist practitioners in developing early interventions at the pre-frail state to prevent or delay subsequent transition to frailty in older IV-infected individuals.
|Day, Gregory S; Gordon, Brian A; Perrin, Richard J et al. (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896-e906|
|Boerwinkle, Anna; Ances, Beau M (2018) Molecular Imaging of Neuroinflammation in HIV. J Neuroimmune Pharmacol :|
|Wright, Patrick W; Archambault, Angela S; Peek, Stacey et al. (2017) Functional connectivity alterations in a murine model of optic neuritis. Exp Neurol 295:18-22|
|Clifford, David B (2017) HIV-associated neurocognitive disorder. Curr Opin Infect Dis 30:117-122|
|Sanford, Ryan; Fernandez Cruz, Ana Lucia; Scott, Susan C et al. (2017) Regionally Specific Brain Volumetric and Cortical Thickness Changes in HIV-Infected Patients in the HAART Era. J Acquir Immune Defic Syndr 74:563-570|
|Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78|
|Paul, Robert; Rhee, Gina; Baker, Laurie M et al. (2017) Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy. J Neurovirol 23:725-733|
|Strain, Jeremy F; Burdo, Tricia H; Song, Sheng-Kwei et al. (2017) Diffusion Basis Spectral Imaging Detects Ongoing Brain Inflammation in Virologically Well-Controlled HIV+ Patients. J Acquir Immune Defic Syndr 76:423-430|
|Mehta, Sanjay R; Pérez-Santiago, Josué; Hulgan, Todd et al. (2017) Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. J Neuroinflammation 14:72|
|Wang, Liang; Benzinger, Tammie L; Su, Yi et al. (2016) Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between ?-Amyloid and Tauopathy. JAMA Neurol 73:1070-7|
Showing the most recent 10 out of 45 publications